STRO Sutro Biopharma, Inc. - Common Stock
$22,94
Prix · Aoû 19, 2026
Données fondamentales au Aoû 12, 2026
Fourchette 52 semaines
$1–$44
51% of range
Note des analystes
BUY
19 analysts
Objectif de cours
$48
+108% upside
P/E (TTM)
-1.0
ROE
232.2%
Marge nette
-186.5%
À propos de Sutro Biopharma, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Lire la suite
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
STRO Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$22.94
Capitalisation Boursière
$197M
P/E (TTM)
-1.0
BPA (TTM)
$-22.49
Revenus (TTM)
$102M
Rendement div.
—
ROE
232.2%
Dette/Capitaux propres
—
Fourchette 52 semaines
$1 – $44
STRO Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$102M
2016-12-31
→
2025-12-31
BPA
$-22.49
2020-12-31
→
2025-12-31
Flux de trésorerie libre
—
2018-12-31
→
2018-12-31
Marges
-186.5%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
STRO
Médiane des pairs
P/E (TTM)
-1.0
6.1
P/S (TTM)
1.9
7.7
P/B
-1.5
2.2
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
STRO
Médiane des pairs
Operating Margin (Marge d'exploitation)
-154.5%
—
Net Profit Margin (Marge nette)
-186.5%
-60.9%
ROA
-68.1%
-50.0%
ROE
232.2%
-44.8%
ROIC
119.5%
—
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
STRO
Médiane des pairs
Current Ratio (Ratio de liquidité)
2.0
5.9
Quick Ratio (Ratio de liquidité réduite)
1.9
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
STRO
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
65.2%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
14.8%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
19.1%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
STRO
Médiane des pairs
STRO Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
19 analystes
- Achat fort 5 26,3%
- Achat 12 63,2%
- Conserver 1 5,3%
- Vente 1 5,3%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
13 analystes · 2026-08-13
Médiane
$50.00
Maintenant
$22.94
Bas
$10.00
Haut
$61.00
Objectif médian
$50.00
+118,0%
Objectif moyen
$47.77
+108,2%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
-0.34%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 31 mars 2026 | $-2.94 | $-3.85 | 0.91% |
| 31 décembre 2025 | $-5.29 | $-4.43 | -0.86% |
| 30 septembre 2025 | $-6.70 | $-4.23 | -2.5% |
| 30 juin 2025 | $-1.40 | $-4.10 | 2.7% |
| 31 mars 2025 | $-9.10 | $-7.22 | -1.9% |
| 31 décembre 2024 | $-8.90 | $-8.48 | -0.42% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | — |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | — |
| SABS | — | — | — | — | — | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 15
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Bilan 24
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Flux de trésorerie 16
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Liquidité et Solvabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Efficacité 2
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Valorisation (TTM) 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Compte de résultat 13
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $9M | $25M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $43M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $58M | $46M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-49M | $-21M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-35M | $-19M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $0 | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-35M | $-19M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | · | $-21M |
Bilan 23
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $47M | $97M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | · | $191M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | · | $11M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | · | $11M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | · | $347M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | · | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | · | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | · | $12M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | · | $10M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | · | $58M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | · | $31M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | · | $133.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | · | $171M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $55.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | · | $-418M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | · | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $217M | $230M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | · | 54,631,360 |
Flux de trésorerie 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $6M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $-24M | $66M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-38M | $-78M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $12M | $30M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $-50M | $18M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Rentabilité 7
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | · | -84.3% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | · | -77.5% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | · | -77.5% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | · | -84.3% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | · | -5.1% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | · | -7.6% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | · |
Liquidité et Solvabilité 4
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | · | 5.9 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | · | 5.1 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
Efficacité 2
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | · | 2.1 |
Valorisation (TTM) 12
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $105M | · | $99M | $115M | $65M | · | $64M | $66M | $53M | · | $65M | $76M | $72M | · | $68M | |
| Net Income TTM | $-145M | $-183M | · | $-193M | $-184M | $-231M | · | $-204M | $-194M | $-196M | · | $-157M | $-134M | $-135M | · | $-116M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | · | $303M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | |
| P/E | -4.6 | -1.9 | · | -0.4 | -0.3 | -0.2 | · | -1.3 | -1.1 | -2.0 | · | -1.3 | -1.9 | -1.8 | · | -2.3 | |
| P/S | 5.6 | 3.9 | · | 0.7 | 0.5 | 0.8 | · | 4.4 | 3.6 | 6.7 | · | 3.2 | 3.7 | 3.9 | · | 4.5 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -1.1 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | |
| Earnings Yield | -22.0% | -51.5% | · | -265.5% | -314.1% | -412.3% | · | -74.6% | -89.8% | -51.1% | · | -77.0% | -51.8% | -56.5% | · | -43.8% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $102M | $62M | $154M | $68M | $62M |
| Marge d'exploitation % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Résultat net | $-191M | $-227M | $-107M | $-119M | $-106M |
| BPA dilué | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dette / Capitaux propres | — | — | 0.0 | 0.1 | 0.1 |
| Ratio de liquidité | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Ratio de liquidité réduite | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 111 déclarants · $467.3M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 46 (+21 vs T. préc.) | 16 (+8 vs T. préc.) | 20 (0 vs T. préc.) | 19 (+5 vs T. préc.) | +1.3M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43 320 887 | 1 304 846 | 9,27% | Actions |
| BVF INC/IL | $41 559 362 | 1 251 788 | 8,89% | Actions |
| Affinity Asset Advisors, LLC | $38 926 568 | 1 172 487 | 8,33% | Actions |
| SAMSARA BIOCAPITAL, LLC | $35 287 350 | 1 062 872 | 7,55% | Actions |
| Kynam Capital Management, LP | $28 968 926 | 872 558 | 6,20% | Actions |
| ORBIMED ADVISORS LLC | $24 698 941 | 743 944 | 5,29% | Actions |
| Balyasny Asset Management L.P. | $23 610 578 | 711 162 | 5,05% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $23 048 071 | 694 219 | 4,93% | Actions |
| EVENTIDE ASSET MANAGEMENT, LLC | $19 430 698 | 585 262 | 4,16% | Actions |
| Velan Capital Investment Management LP | $17 003 712 | 512 160 | 3,64% | Actions |
| Woodline Partners LP | $15 206 563 | 458 029 | 3,25% | Actions |
| ADAR1 Capital Management, LLC | $13 413 265 | 404 014 | 2,87% | Actions |
| MILLENNIUM MANAGEMENT LLC | $12 150 270 | 365 972 | 2,60% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $11 027 500 | 332 057 | 2,36% | Actions |
| STATE STREET CORP | $10 158 503 | 305 979 | 2,17% | Actions |
| Merck & Co., Inc. | $9 042 053 | 272 351 | 1,93% | Actions |
| ACUTA CAPITAL PARTNERS, LLC | $8 972 333 | 270 251 | 1,92% | Actions |
| AMERIPRISE FINANCIAL INC | $8 123 011 | 244 669 | 1,74% | Actions |
| Point72 Asset Management, L.P. | $7 895 856 | 237 827 | 1,69% | Actions |
| KVP Capital Advisors, LP | $7 522 290 | 226 575 | 1,61% | Actions |
| TWO SIGMA INVESTMENTS, LP | $6 696 042 | 201 688 | 1,43% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6 559 058 | 197 562 | 1,40% | Actions |
| UBS Group AG | $5 407 251 | 162 869 | 1,16% | Actions |
| Seven Fleet Capital Management LP | $3 794 182 | 159 118 | 0,81% | Actions |
| Qube Research & Technologies Ltd | $3 539 452 | 106 610 | 0,76% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $3 460 502 | 104 232 | 0,74% | Actions |
| CITADEL ADVISORS LLC | $3 385 205 | 101 964 | 0,72% | Actions |
| MACKENZIE FINANCIAL CORP | $3 146 264 | 94 767 | 0,67% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $2 865 957 | 86 324 | 0,61% | Actions |
| MARSHALL WACE, LLP | $2 448 865 | 73 761 | 0,52% | Actions |
| Y-Intercept (Hong Kong) Ltd | $1 855 183 | 55 879 | 0,40% | Actions |
| Squarepoint Ops LLC | $1 843 895 | 55 539 | 0,39% | Actions |
| XTX Topco Ltd | $1 732 011 | 52 169 | 0,37% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1 636 826 | 49 302 | 0,35% | Actions |
| Sigma Planning Corp | $1 494 664 | 45 020 | 0,32% | Actions |
| Fisher Asset Management, LLC | $1 171 794 | 35 295 | 0,25% | Actions |
| Elmind Capital, LP | $1 063 628 | 32 037 | 0,23% | Actions |
| D. E. Shaw & Co., Inc. | $1 000 250 | 30 128 | 0,21% | Actions |
| GOLDMAN SACHS GROUP INC | $975 814 | 29 392 | 0,21% | Actions |
| Trexquant Investment LP | $917 515 | 27 636 | 0,20% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $909 116 | 27 383 | 0,19% | Actions |
| BANK OF AMERICA CORP /DE/ | $863 897 | 26 021 | 0,18% | Actions |
| RHUMBLINE ADVISERS | $684 845 | 20 628 | 0,15% | Actions |
| JPMORGAN CHASE & CO | $625 079 | 18 743 | 0,13% | Actions |
| BlackRock, Inc. | $595 276 | 17 930 | 0,13% | Actions |
| SEI INVESTMENTS CO | $544 048 | 16 387 | 0,12% | Actions |
| Informed Momentum Co LLC | $538 902 | 16 232 | 0,12% | Actions |
| DEUTSCHE BANK AG\ | $516 692 | 15 563 | 0,11% | Actions |
| RBF Capital, LLC | $507 030 | 15 272 | 0,11% | Actions |
| WELLS FARGO & COMPANY/MN | $449 661 | 13 544 | 0,10% | Actions |
| AJU IB Investment Co., Ltd. | $435 925 | 17 500 | 0,09% | Actions |
| Bank of New York Mellon Corp | $434 522 | 13 088 | 0,09% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $368 520 | 11 100 | 0,08% | Option d'achat |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $365 200 | 11 000 | 0,08% | Option de vente |
| MetLife Investment Management, LLC | $312 113 | 9 401 | 0,07% | Actions |
| Walleye Capital LLC | $308 959 | 9 306 | 0,07% | Actions |
| Integrated Quantitative Investments LLC | $296 775 | 8 939 | 0,06% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $279 743 | 8 426 | 0,06% | Actions |
| Lighthouse Investment Partners, LLC | $277 818 | 8 368 | 0,06% | Actions |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $242 792 | 7 313 | 0,05% | Actions |
| ALLIANCEBERNSTEIN L.P. | $242 360 | 7 300 | 0,05% | Actions |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $232 433 | 7 001 | 0,05% | Actions |
| Persistent Asset Partners Ltd | $218 091 | 6 569 | 0,05% | Actions |
| CITIGROUP INC | $216 995 | 6 536 | 0,05% | Actions |
| Verdad Advisers, LP | $212 480 | 6 400 | 0,05% | Actions |
| Invesco Ltd. | $211 119 | 6 359 | 0,05% | Actions |
| HSBC HOLDINGS PLC | $205 722 | 6 234 | 0,04% | Actions |
| TWO SIGMA ADVISERS, LP | $203 401 | 17 580 | 0,04% | Actions |
| NEW YORK STATE COMMON RETIREMENT FUND | $185 920 | 5 600 | 0,04% | Actions |
| MORGAN STANLEY | $181 870 | 5 478 | 0,04% | Actions |
| Vanguard Global Advisers, LLC | $180 774 | 5 445 | 0,04% | Actions |
| Police & Firemen's Retirement System of New Jersey | $156 173 | 4 704 | 0,03% | Actions |
| Nuveen, LLC | $131 837 | 3 971 | 0,03% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $119 520 | 3 600 | 0,03% | Actions |
| Nuveen Asset Management, LLC | $103 678 | 56 347 | 0,02% | Actions |
| BARCLAYS PLC | $84 228 | 2 537 | 0,02% | Actions |
| NORTHERN TRUST CORP | $83 100 | 2 503 | 0,02% | Actions |
| State of Wyoming | $53 718 | 1 618 | 0,01% | Actions |
| Legal & General Group Plc | $51 394 | 1 548 | 0,01% | Actions |
| Ameritas Investment Partners, Inc. | $48 074 | 1 448 | 0,01% | Actions |
| FMR LLC | $44 388 | 1 337 | 0,01% | Actions |
| Russell Investments Group, Ltd. | $42 330 | 1 275 | 0,01% | Actions |
| VANGUARD GROUP INC | $36 307 | 3 138 | 0,01% | Actions |
| Tower Research Capital LLC (TRC) | $28 751 | 866 | 0,01% | Actions |
| Point72 Asia (Singapore) Pte. Ltd. | $26 943 | 31 026 | 0,01% | Actions |
| CWM, LLC | $24 487 | 983 | 0,01% | Actions |
| ROYAL BANK OF CANADA | $23 000 | 687 | 0,00% | Actions |
| Owl Creek Wealth Partners LLC | $16 302 | 491 | 0,00% | Actions |
| ACADIAN ASSET MANAGEMENT LLC | $12 405 | 373 839 | 0,00% | Actions |
| Sterling Capital Management LLC | $9 329 | 281 | 0,00% | Actions |
| Quantbot Technologies LP | $6 673 | 201 | 0,00% | Actions |
| Physician Wealth Advisors, Inc. | $6 043 | 182 | 0,00% | Actions |
| MERCER GLOBAL ADVISORS INC /ADV | $3 718 | 112 | 0,00% | Actions |
| OSAIC HOLDINGS, INC. | $3 320 | 100 | 0,00% | Actions |
| PNC Financial Services Group, Inc. | $2 058 | 62 | 0,00% | Actions |
| Fortitude Family Office, LLC | $1 859 | 56 | 0,00% | Actions |
| Bogart Wealth, LLC | $1 660 | 50 | 0,00% | Actions |
| Parallel Advisors, LLC | $1 560 | 47 | 0,00% | Actions |
| NISA INVESTMENT ADVISORS, LLC | $1 461 | 44 | 0,00% | Actions |
| Accredited Wealth Management, LLC | $869 | 5 | 0,00% | Actions |
Initiés de la société 27 initiés · 14 dirigeants · 14 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| William J Newell | CEO | 3 mars 2023 M | 164 816 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 2 juin 2026 M | 4 725 | 0 | 0 | $0 |
| Edward C Albini | CFO and Secretary | 3 mars 2023 M | 87 693 | 0 | 0 | $0 |
| Jane Chung | President and COO | 1 décembre 2023 A | 31 698 | 0 | 0 | $0 |
| Hans-Peter Gerber | Chief Scientific Officer | 18 septembre 2023 A | — | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28 août 2023 S | 0 | 0 | 0 | $0 |
| Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | 12 juillet 2023 M | 24 988 | 0 | 0 | $0 |
| Venkatesh Srinivasan | Chief Tech Op Officer | 1 mai 2023 A | — | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14 avril 2023 M | 100 368 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Chief Medical Officer | 15 mars 2023 A | — | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 3 mars 2023 M | 40 827 | 0 | 0 | $0 |
| Linda A Fitzpatrick | Chief People & Comm. Officer | 3 mars 2023 M | 52 690 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 5 mars 2022 M | 37 736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29 janvier 2019 A | — | 0 | 0 | $0 |
| Heidi Hunter | Administrateur | 5 juin 2026 A | — | 0 | 0 | $0 |
| Michael Dybbs | Administrateur | 5 juin 2026 A | — | 0 | 0 | $0 |
| Jon Marc Wigginton | Administrateur | 5 juin 2026 A | — | 0 | 0 | $0 |
| Sukhi Jagpal | Administrateur | 5 juin 2026 A | — | 0 | 0 | $0 |
| Joseph M Lobacki | Administrateur | 5 juin 2026 A | — | 0 | 0 | $0 |
| Daniel H Petree | Administrateur | 5 juin 2026 A | 18 601 | 0 | 0 | $0 |
| Connie Matsui | Administrateur | 5 juin 2026 A | 50 000 | 1 | 0 | $40 000 |
| James P Panek | Administrateur | 5 juin 2026 A | — | 0 | 0 | $0 |
| John Gordon Freund | Administrateur | 8 juin 2023 A | 56 327 | 0 | 0 | $0 |
| Shalini Sharp | Administrateur | 6 juin 2022 A | — | 0 | 0 | $0 |
| Daniel Janney | Administrateur | 17 juin 2019 A | 1 944 901 | 0 | 0 | $0 |
| Michael Jay Ross | Administrateur | 1 octobre 2018 C | 18 248 | 0 | 0 | $0 |
| Bryan V Lawlis | Administrateur | 26 septembre 2018 A | — | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 1 participation
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 9 octobre 2018 | — | Dépôt initial | Investissement passif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 15 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 3 826 SH | 8 août 2026 | Quotidien |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,25% | 28 745 SH | 8 août 2026 | Quotidien |
| IWC · iShares Trust | 0,09% | 54 216 SH | 8 août 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11 715 SH | 8 août 2026 | Quotidien |
| IWN · iShares Trust | 0,02% | 121 308 SH | 8 août 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91 894 SH | 8 août 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 16 520 SH | 8 août 2026 | Quotidien |
| IWM · iShares Trust | 0,01% | 398 610 SH | 8 août 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177 152 SH | 8 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,01% | 47 358 SH | 8 août 2026 | Quotidien |
| IWO · iShares Trust | 0,00% | 22 665 SH | 8 août 2026 | Quotidien |
| ITOT · iShares Trust | 0,00% | 29 451 SH | 8 août 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501 524 SH | 8 août 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 670 SH | 8 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1 330 SH | 8 août 2026 | Quotidien |